# Amylyx Pharmaceuticals Inc. (AMLX)

Source: https://www.quantisnow.com/company/AMLX
Generated: 2026-11-11T13:18:28.855Z

- Ticker: AMLX
- Exchange: NASDAQ
- Sector: Health Care
- Industry: Biotechnology: Pharmaceutical Preparations
- IPO year: 2022
- SEC CIK: 0001658551
- Website: https://amylyx.com

## About

Amylyx Pharmaceuticals, Inc., a biopharmaceutical company, develops therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases in the United States and Canada. The company's product candidature includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and tauroursodeoxycholic acid for the treatment of ALS and other neurodegenerative diseases. It is also developing products for Wolfram syndrome and Alzheimer's diseases. Amylyx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.

## Latest AMLX news and filings

- 2026-11-09 21:36 UTC [SEC Form 144] [SEC Form 144 filed by Amylyx Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-144-filed-by-amylyx-pharmaceuticals-inc-6781792)
- 2026-11-05 12:02 UTC [SEC Form 8-K] [Amylyx Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits](https://www.quantisnow.com/insight/amylyx-pharmaceuticals-inc-filed-sec-form-8-k-results-of-operations-6774534)
- 2026-11-05 12:04 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by Amylyx Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-amylyx-pharmaceuticals-inc-6774517)
- 2026-11-05 12:00 UTC [Earnings] [Amylyx Pharmaceuticals Reports Third Quarter 2026 Financial Results](https://www.quantisnow.com/insight/amylyx-pharmaceuticals-reports-third-quarter-2026-financial-results-6774384)
- 2026-11-04 14:00 UTC [Conference Announcement] [Amylyx Pharmaceuticals to Host Investor Event at ObesityWeek® 2026 Featuring Leading PBH Experts](https://www.quantisnow.com/insight/amylyx-pharmaceuticals-to-host-investor-event-at-obesityweek-2026-featuring-6771679)
- 2026-11-03 14:00 UTC [Conference Announcement] [Amylyx Pharmaceuticals to Participate in Upcoming November Investor Conferences](https://www.quantisnow.com/insight/amylyx-pharmaceuticals-to-participate-in-upcoming-november-investor-conferences-6768820)
- 2026-11-02 14:00 UTC [Earnings Date] [Amylyx Pharmaceuticals to Report Third Quarter 2026 Financial Results on November 5, 2026](https://www.quantisnow.com/insight/amylyx-pharmaceuticals-to-report-third-quarter-2026-financial-results-on-6766432)
- 2026-10-07 20:00 UTC [SEC Form 4] [Director Milne George M Jr sold $830,904 worth of shares (30,000 units at $27.70) as part of a pre-agreed trading plan (SEC Form 4)](https://www.quantisnow.com/insight/director-milne-george-m-jr-sold-830904-worth-of-shares-6740229)
- 2026-10-06 12:00 UTC [Amylyx Pharmaceuticals to Present Topline Data from Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia at ObesityWeek® 2026 Annual Meeting](https://www.quantisnow.com/insight/amylyx-pharmaceuticals-to-present-topline-data-from-phase-3-lucidity-6738204)
- 2026-10-05 20:38 UTC [SEC Form 144] [SEC Form 144 filed by Amylyx Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-144-filed-by-amylyx-pharmaceuticals-inc-6737209)
- 2026-09-23 13:00 UTC [Conference Announcement] [Amylyx Pharmaceuticals to Present at the Stifel 2026 Virtual Cardiometabolic Forum](https://www.quantisnow.com/insight/amylyx-pharmaceuticals-to-present-at-the-stifel-2026-virtual-cardiometabolic-6723839)
- 2026-09-14 20:00 UTC [SEC Form 4] [Co-Chief Executive Officer Klee Justin B. sold $980,263 worth of shares (30,464 units at $32.18), decreasing direct ownership by 0.84% to 3,613,056 units (SEC Form 4) (for tax liability)](https://www.quantisnow.com/insight/co-chief-executive-officer-klee-justin-b-sold-980263-worth-of-6714345)
- 2026-09-14 20:00 UTC [SEC Form 4] [Co-Chief Executive Officer Cohen Joshua B sold $980,504 worth of shares (30,464 units at $32.19), decreasing direct ownership by 0.84% to 3,613,123 units (SEC Form 4) (tax withholding)](https://www.quantisnow.com/insight/co-chief-executive-officer-cohen-joshua-b-sold-980504-worth-of-6714341)
- 2026-09-14 20:00 UTC [SEC Form 4] [Chief Legal Officer Mazzariello Gina sold $309,506 worth of shares (9,536 units at $32.46), decreasing direct ownership by 5% to 190,838 units (SEC Form 4) to cover taxes](https://www.quantisnow.com/insight/chief-legal-officer-mazzariello-gina-sold-309506-worth-of-shares-6714339)
- 2026-09-14 20:00 UTC [SEC Form 4] [Chief Financial Officer Frates James M sold $349,821 worth of shares (10,810 units at $32.36), decreasing direct ownership by 4% to 233,625 units (SEC Form 4) to satisfy tax liability](https://www.quantisnow.com/insight/chief-financial-officer-frates-james-m-sold-349821-worth-of-6714338)
- 2026-09-14 20:00 UTC [SEC Form 4] [Chief Medical Officer Bedrosian Camille L sold $324,868 worth of shares (10,028 units at $32.40), decreasing direct ownership by 3% to 278,064 units (SEC Form 4) to satisfy tax liability](https://www.quantisnow.com/insight/chief-medical-officer-bedrosian-camille-l-sold-324868-worth-of-6714336)
- 2026-09-11 20:01 UTC [SEC Form 144] [SEC Form 144 filed by Amylyx Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-144-filed-by-amylyx-pharmaceuticals-inc-6712872)
- 2026-09-11 20:01 UTC [SEC Form 144] [SEC Form 144 filed by Amylyx Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-144-filed-by-amylyx-pharmaceuticals-inc-6712864)
- 2026-09-09 12:00 UTC [Leadership Update] [Tortugas Neuroscience Announces Appointment of Jim Frates to Board of Directors](https://www.quantisnow.com/insight/tortugas-neuroscience-announces-appointment-of-jim-frates-to-board-of-6709301)
- 2026-09-08 20:54 UTC [SEC Form 8-K] [SEC Form 8-K filed by Amylyx Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-8-k-filed-by-amylyx-pharmaceuticals-inc-6708609)
- 2026-09-08 13:00 UTC [Conference Announcement] [Amylyx Pharmaceuticals to Present at the 24th Annual Morgan Stanley Global Healthcare Conference](https://www.quantisnow.com/insight/amylyx-pharmaceuticals-to-present-at-the-24th-annual-morgan-stanley-6707812)
- 2026-09-02 20:00 UTC [SEC Form 4] [Director Firestone Karen exercised 50,000 shares at a strike of $3.40, increasing direct ownership by 75% to 116,900 units (SEC Form 4)](https://www.quantisnow.com/insight/director-firestone-karen-exercised-50000-shares-at-a-strike-of-6702968)
- 2026-08-21 01:00 UTC [SEC Form 4] [Chief Financial Officer Frates James M was granted 22,807 shares, increasing direct ownership by 10% to 244,435 units (SEC Form 4)](https://www.quantisnow.com/insight/chief-financial-officer-frates-james-m-was-granted-22807-shares-6690622)
- 2026-08-21 01:00 UTC [SEC Form 4] [Co-Chief Executive Officer Klee Justin B. was granted 60,039 shares, increasing direct ownership by 2% to 3,643,520 units (SEC Form 4)](https://www.quantisnow.com/insight/co-chief-executive-officer-klee-justin-b-was-granted-60039-shares-6690619)
- 2026-08-21 01:00 UTC [SEC Form 4] [Chief Legal Officer Mazzariello Gina was granted 21,284 shares, increasing direct ownership by 12% to 200,374 units (SEC Form 4)](https://www.quantisnow.com/insight/chief-legal-officer-mazzariello-gina-was-granted-21284-shares-increasing-6690618)
- 2026-08-21 01:00 UTC [SEC Form 4] [Co-Chief Executive Officer Cohen Joshua B was granted 60,039 shares, increasing direct ownership by 2% to 3,643,587 units (SEC Form 4)](https://www.quantisnow.com/insight/co-chief-executive-officer-cohen-joshua-b-was-granted-60039-shares-6690615)
- 2026-08-21 01:00 UTC [SEC Form 4] [Chief Medical Officer Bedrosian Camille L was granted 22,807 shares, increasing direct ownership by 9% to 288,092 units (SEC Form 4)](https://www.quantisnow.com/insight/chief-medical-officer-bedrosian-camille-l-was-granted-22807-shares-6690614)
- 2026-08-20 21:27 UTC [SEC Form 424B5] [SEC Form 424B5 filed by Amylyx Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-424b5-filed-by-amylyx-pharmaceuticals-inc-6690442)
- 2026-08-20 21:28 UTC [SEC Form 8-K] [SEC Form 8-K filed by Amylyx Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-8-k-filed-by-amylyx-pharmaceuticals-inc-6690440)
- 2026-08-20 03:06 UTC [Public Offering] [Amylyx Pharmaceuticals Announces Pricing of an Upsized $500 Million Underwritten Public Offering of Common Stock](https://www.quantisnow.com/insight/amylyx-pharmaceuticals-announces-pricing-of-an-upsized-500-million-underwritten-6689182)
- 2026-08-18 21:17 UTC [SEC Form 424B5] [SEC Form 424B5 filed by Amylyx Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-424b5-filed-by-amylyx-pharmaceuticals-inc-6687149)
- 2026-08-18 20:01 UTC [Public Offering] [Amylyx Pharmaceuticals Announces $350.0 Million Proposed Public Offering of Common Stock](https://www.quantisnow.com/insight/amylyx-pharmaceuticals-announces-3500-million-proposed-public-offering-of-common-6686407)
- 2026-08-18 13:03 UTC [SEC Form 8-K] [SEC Form 8-K filed by Amylyx Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-8-k-filed-by-amylyx-pharmaceuticals-inc-6686117)
- 2026-08-18 11:09 UTC [SEC Form 8-K] [Amylyx Pharmaceuticals Inc. filed SEC Form 8-K: Regulation FD Disclosure](https://www.quantisnow.com/insight/amylyx-pharmaceuticals-inc-filed-sec-form-8-k-regulation-fd-disclosure-6685833)
- 2026-08-18 11:00 UTC [Earnings Date] [Amylyx Pharmaceuticals Announces Positive Topline Results from Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia](https://www.quantisnow.com/insight/amylyx-pharmaceuticals-announces-positive-topline-results-from-phase-3-lucidity-6685803)
- 2026-08-17 20:01 UTC [Earnings Date] [Amylyx Pharmaceuticals to Announce Topline Results from its Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia on August 18, 2026](https://www.quantisnow.com/insight/amylyx-pharmaceuticals-to-announce-topline-results-from-its-phase-3-6684846)
- 2026-08-06 11:04 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by Amylyx Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-amylyx-pharmaceuticals-inc-6667163)
- 2026-08-06 11:02 UTC [SEC Form 8-K] [Amylyx Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits](https://www.quantisnow.com/insight/amylyx-pharmaceuticals-inc-filed-sec-form-8-k-results-of-operations-6667143)
- 2026-08-06 11:00 UTC [Earnings Date] [Amylyx Pharmaceuticals Reports Second Quarter 2026 Financial Results](https://www.quantisnow.com/insight/amylyx-pharmaceuticals-reports-second-quarter-2026-financial-results-6667031)
- 2026-08-03 13:00 UTC [Earnings Date] [Amylyx Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 6, 2026](https://www.quantisnow.com/insight/amylyx-pharmaceuticals-to-report-second-quarter-2026-financial-results-on-6659000)

## More

- Live page with ratings, short volume, options and peers: https://www.quantisnow.com/company/AMLX
- Earnings history: https://www.quantisnow.com/earnings/AMLX
- Dividend history: https://www.quantisnow.com/dividends/AMLX
- Insider transactions: https://www.quantisnow.com/insiders/AMLX
- Options chain: https://www.quantisnow.com/options/AMLX
- SEC 8-K filings only: https://www.quantisnow.com/company/AMLX/8-k
- RSS and alerts for AMLX: https://www.quantisnow.com/docs/rss-feeds.md